CORCEPT THERAPEUTICS INC filed a 144

Here is how Aspen Pharmacare (APNHY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.

Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Rivian Automotive Inc (Symbol: RIVN), where a total volume of 107,237 contracts has been traded thus far today, a contract volume which is representative of appr

Notable Tuesday Option Activity: RIVN, CORT, AAOI

Insider reported a trade at CORCEPT THERAPEUTICS INC

BUFFALO Funds, an actively managed mutual fund advised by Kornitzer Capital Management, released its second-quarter 2026 investor letter for “Buffalo Mid Cap Discovery Fund”. The letter can be downloaded here. The Fund returned 11.34% in the quarter, underperforming its benchmark, the Russell Midcap Growth Index, which returned 14.55%. First-half gains were led by Industrials, Financials, […]

Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)

REDWOOD CITY, Calif., September 23, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting Octobe

Corcept Announces Planned Leadership Transition

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Corcept Therapeutics Incorporated News